Rebimastat

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRebimastat
Drug Alias Namerebimastatum瑞马司他rebimastatD-2163BMS-275291
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMatrix metalloproteinase 14 inhibitorsMatrix metalloproteinase 9 inhibitorsMatrix metalloproteinase-2 inhibitors +[4] 
TargetsMatrix metalloproteinase 9Matrix metalloproteinase-1Matrix metalloproteinase 14 +[4] 
Therapy Area/IndicationsBone metastasesHormone-Resistant Prostate NeoplasmsProstatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCelltech
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb SrlcompanyCelltechNational Cancer Institute +[4] 
Active IndicationsN/A
Inactive IndicationsBone metastasesHormone-Resistant Prostate NeoplasmsProstatic Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksKEGG